TrialCurveSequential vs upfront oxaliplatin in metastatic colorectal cancer: reconstructed Kaplan–Meier curves
Sequential versus upfront oxaliplatin-based therapy in metastatic colorectal cancer: long-term outcomes of a randomized phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Commun Med (Lond). 2026 May 8;6:394. doi: 10.1038/s43856-026-01633-3 |
|---|---|
| DOI | 10.1038/s43856-026-01633-3 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — Full analysis set
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: A 27.2 months; B 27.5 months. Survival at 18 months: A 76%; B 70%. Hazard ratio A vs B 0.99 (95% CI 0.74–1.31).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| A | 151 | 93 | 27.2 |
| B | 149 | 102 | 27.5 |
- A vs B: reconstructed HR 0.99 (95% CI 0.74–1.31)
Landmark survival (reconstructed)
| Time | A | B |
|---|---|---|
| 6 mo | 94.7% | 93.3% |
| 12 mo | 88.7% | 81.8% |
| 18 mo | 75.6% | 70.2% |
| 24 mo | 59.7% | 57.5% |
| 36 mo | 40.1% | 42.9% |
| 48 mo | 25.9% | 30.2% |
| 60 mo | — | 8.2% |
Checks against the published figure
- A median: printed 27.2, reconstructed 27.2 pass
- B median: printed 27.4, reconstructed 27.5 pass
- hazard ratio: printed 1, reconstructed 1.01 pass
Overall survival — Full analysis set stratified by age (<70 vs >=70 years) within each arm
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: A, <70 32.6 months; B, <70 39.6 months; A, ≥70 26.1 months; B, ≥70 25.6 months. Survival at 18 months: A, <70 78%; B, <70 78%; A, ≥70 73%; B, ≥70 64%. Hazard ratio A, <70 vs B, ≥70 0.64 (95% CI 0.43–0.94).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| A, <70 | 79 | 44 | 32.6 |
| B, <70 | 72 | 43 | 39.6 |
| A, ≥70 | 72 | 50 | 26.1 |
| B, ≥70 | 77 | 60 | 25.6 |
- A, <70 vs B, ≥70: reconstructed HR 0.64 (95% CI 0.43–0.94)
- B, <70 vs B, ≥70: reconstructed HR 0.58 (95% CI 0.38–0.86)
- A, ≥70 vs B, ≥70: reconstructed HR 0.93 (95% CI 0.64–1.35)
Landmark survival (reconstructed)
| Time | A, <70 | B, <70 | A, ≥70 | B, ≥70 |
|---|---|---|---|---|
| 6 mo | 98.7% | 94.4% | 90.3% | 92.2% |
| 12 mo | 89.9% | 87.5% | 87.5% | 76.6% |
| 18 mo | 78.1% | 77.7% | 73.2% | 63.6% |
| 24 mo | 62.9% | 64.6% | 55.6% | 50.4% |
| 36 mo | 47.5% | 53.6% | 32.1% | 33.6% |
| 48 mo | 35.1% | 44.3% | 17.0% | 19.1% |
| 60 mo | — | 12.7% | — | — |
Checks against the published figure
- A, <70 median: printed 32.6, reconstructed 32.6 pass
- A, ≥70 median: printed 26.2, reconstructed 26.1 pass
- B, <70 median: printed 39.6, reconstructed 39.6 pass
- B, ≥70 median: printed 25.4, reconstructed 25.6 pass
- hazard ratio: printed 1.44, reconstructed 1.43 pass
- hazard ratio: printed 1.77, reconstructed 1.74 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- XELOX + bevacizumab ± adoptive cell immunotherapy in colorectal cancer: Overall survival; Progression-free survival
- BREAKWATER: Overall survival
- Cetuximab β + FOLFIRI in RAS/BRAF wild-type colorectal cancer: Overall survival; Progression-free survival (BIRC-assessed)
- SCOT: Disease-free survival; Overall survival; Survival after recurrence (SAR)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials